CraigDScovilleMD

Rheumatology • Idaho Falls, ID

Rheumatoid Arthritis & Related, Spondyloarthropathy

Physician

Join to view full profile

Dr. Scoville is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Scoville's full profile

Already have an account?

Office
2220 E 25th St
Idaho Falls, ID 83404
Phone+1 208-542-9080

Fax+1 208-542-9081

Education & Training

UCLA David Geffen School of Medicine/UCLA Medical CenterFellowship, Rheumatology, 1985 - 1987
University of WashingtonResidency, Internal Medicine, 1982 - 1985
University of Rochester School of Medicine and DentistryClass of 1982

Certifications & Licensure

CA State Medical License 1985 - Present
ID State Medical License 1987 - 2026
WY State Medical License 1994 - 1997
WA State Medical License 1983 - 1987
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Rheumatology

Awards, Honors, & Recognition

Regional Top Doctor Castle Connolly, 2014
Fellow (FACR) American College of Rheumatology

Clinical Trials

A Study of LY3337641 in Rheumatoid Arthritis Start of enrollment: 2016 Aug 22
Terminated
Phase 2
A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis Start of enrollment: 2016 May 02
Completed
Phase 3
A Study of Ixekizumab (LY2439821) in TNF Inhibitor Experienced Participants With Radiographic Axial Spondyloarthritis Start of enrollment: 2016 Apr 12
Completed
Phase 3
A Study of Ixekizumab (LY2439821) in Participants With Nonradiographic Axial Spondyloarthritis Start of enrollment: 2016 Aug 02
Completed
Phase 3
A Long Term Extension Study of Ixekizumab (LY2439821) in Participants With Axial Spondyloarthritis Start of enrollment: 2017 May 09
Completed
Phase 3
Efficacy and Safety of GSK3196165 Versus Placebo and Tofacitinib in Participants With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic (cs)/Biologic (b) Disease Modifying Anti-rheumatic Drugs (DMARDs) Start of enrollment: 2019 Jun 05
Terminated
Phase 3
Comparing the Incidence of Preeclampsia Between Pregnant Women Receiving Tdap Vaccinations at Week 28 or at Week 36 Start of enrollment: 2020 Dec 01
Not yet recruiting
Phase 4
Join now to see all

Publications & Presentations

PubMed

9 citations
Plasma angiotensin peptides as biomarkers of rheumatoid arthritis are correlated with anti-ACE2 auto-antibodies level and disease intensity.
Sana Khajeh Pour, Craig Scoville, Susan S Tavernier, Ali Aghazadeh-Habashi
Inflammopharmacology. 2022-08-01
A pilot study of the relationship between preeclampsia and anti-tetanus toxoid antibody levels.
Craig D. Scoville, Glenn R. Leavitt, Maritza Rosales, H. Dennis Tolley
Pregnancy Hypertension. 2017-08-24
1 citations
Description and characterization of a unique human immunoglobulin G1 kappa idiotype found in placental tissue.
Craig D. Scoville, Devon Rasmussen
Placenta. 2017-02-01

Professional Memberships

American College of Rheumatology - ACR
Fellow